Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMMX Immix Biopharma, Inc.

Pre-Mkt 12-12 08:07:43 EST

7.38

+0.65

+9.66%

盘前7.50

+0.12+1.63%

08:00 EST

High7.45	Low6.61	Vol1.97M
Open6.82	D1 Closing6.73	Amplitude12.41%
Mkt Cap384.89M	Tradable Cap305.82M	Total Shares52.15M
T/O13.99M	T/O Rate4.75%	Tradable Shares41.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":7.38,"timestamp":1765486800000,"preClose":6.73,"halted":0,"volume":1967851,"hourTrading":{"tag":"盘前","latestPrice":7.5,"preClose":7.38,"latestTime":"08:00 EST","volume":2033,"amount":15312.139234999999,"timestamp":1765544407063},"delay":0,"floatShares":41439399,"shares":52153200,"eps":-0.777635,"marketStatus":"Pre-Mkt","change":0.65,"latestTime":"12-12 08:07:43 EST","open":6.82,"high":7.445,"low":6.6101,"amount":13986125.122959,"amplitude":0.124056,"askPrice":7.96,"askSize":200,"bidPrice":7.09,"bidSize":8,"shortable":3,"etf":0,"ttmEps":-0.777635,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765549800000},"marketStatusCode":1,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":7.38,"preHourTrading":{"tag":"盘前","latestPrice":7.5,"preClose":7.38,"latestTime":"08:00 EST","volume":2033,"amount":15312.139234999999,"timestamp":1765544407063},"postHourTrading":{"tag":"盘后","latestPrice":7.26,"preClose":7.38,"latestTime":"19:49 EST","volume":7534,"amount":55207.6067,"timestamp":1765500598694},"volumeRatio":0.6855174790897216,"impliedVol":1.6479,"impliedVolPercentile":0.747},"requestUrl":"/m/hq/s/IMMX/wiki","defaultTab":"wiki","newsList":[{"id":"2590551333","title":"Immix Biopharma CEO Ilya Rachman Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590551333","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590551333?lang=en_us&edition=fundamental","pubTime":"2025-12-11 07:49","pubTimestamp":1765410593,"startTime":"0","endTime":"0","summary":"Ilya M. Rachman, CEO and Chairman of Immix Biopharma Inc., has reported the acquisition of common shares of Immix Biopharma Inc., according to a recent regulatory filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL8nZV0Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immix Biopharma CEO Ilya Rachman Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2590551809","title":"Immix Biopharma CFO Gabriel S. Morris Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590551809","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590551809?lang=en_us&edition=fundamental","pubTime":"2025-12-11 07:47","pubTimestamp":1765410469,"startTime":"0","endTime":"0","summary":"Gabriel S. Morris, Chief Financial Officer and Director of Immix Biopharma Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL5db4Tx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2590732745","title":"BRIEF-Immix Biopharma Announces Closing Of Upsized $100 Million Underwritten Offering Of Common Stock And Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2590732745","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590732745?lang=en_us&edition=fundamental","pubTime":"2025-12-10 06:52","pubTimestamp":1765320735,"startTime":"0","endTime":"0","summary":"BRIEF-Immix Biopharma Announces Closing Of Upsized $100 Million Underwritten Offering Of Common Stock And Pre-Funded WarrantsDec 9 (Reuters) - Immix Biopharma Inc IMMX.O:IMMIX BIOPHARMA ANNOUNCES CLOS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA88X000:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2590534099","title":"Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2590534099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590534099?lang=en_us&edition=fundamental","pubTime":"2025-12-09 23:42","pubTimestamp":1765294920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 10:42 ET (15:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2590349704","title":"Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $12 From $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349704?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:25","pubTimestamp":1765286716,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nAZN4RCE0E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2590350585","title":"Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2590350585","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590350585?lang=en_us&edition=fundamental","pubTime":"2025-12-09 01:54","pubTimestamp":1765216448,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLb7mdvW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2589801811","title":"BRIEF-Immix Biopharma Prices Offering Of 19.1 Million  Shares  At $5.10 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801811","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801811?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:22","pubTimestamp":1765149758,"startTime":"0","endTime":"0","summary":"BRIEF-Immix Biopharma Prices Offering Of 19.1 Million  Shares  At $5.10 Per ShareDec 8 (Reuters) - Immix Biopharma Inc IMMX.O:IMMIX BIOPHARMA ANNOUNCES PRICING OF UPSIZED $100 MILLION UNDERWRITTEN OFF","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUA408RKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2589856801","title":"Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2589856801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589856801?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:20","pubTimestamp":1765149602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUA408RKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2589801855","title":"Immix Biopharma Inc - Prices Offering of 19.12 Mln  Shares  at $5.10 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801855?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:20","pubTimestamp":1765149602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUA408RKK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2589809706","title":"Immix Biopharma Reports 75% Complete Response Rate in Phase 2 NXC-201 Trial for Relapsed/Refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589809706","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589809706?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:15","pubTimestamp":1765149317,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on December 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL9YT2sp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210149790.SGD","IMMX","LU2210150020.SGD","SG9999014005.SGD","BK4139","NDAQ","IE00BKPKM429.USD","SG9999014013.SGD","BK4112","BK4588","SG9999014021.USD","BK4585","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2589809766","title":"at Ash 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 Nxc-201 Results, Advancing Toward Bla Submission as a Potentially First- and Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589809766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589809766?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:15","pubTimestamp":1765149300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUA3KCQML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2588057172","title":"Immix Biopharma Unveils Breakthrough Strategy for Relapsed/Refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2588057172","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588057172?lang=en_us&edition=fundamental","pubTime":"2025-12-03 00:44","pubTimestamp":1764693877,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. has released a presentation highlighting the challenges faced by patients with relapsed or refractory AL amyloidosis in the United States. The document reports that approximately 38,500 US patients are affected by this rare disease, which involves the accumulation of toxic light chains that damage major organs such as the heart, kidneys, and liver. The presentation notes that there are currently no FDA-approved therapies for patients who relapse after first-line treatment, and available second-line therapies demonstrate low complete response rates of 0-10%. Treatment options are limited, often involving the reuse of older drugs with limited efficacy. The presentation references multiple studies to support these findings and emphasizes the need for improved therapeutic options for this patient population. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligenc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL2s1gy8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2582374285","title":"Immix Biopharma Appoints Michael Grabow as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374285","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374285?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:45","pubTimestamp":1762955121,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL77NvKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","LU0320765992.SGD","BK4112","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4533","LU0109394709.USD","BK4007","BK4532","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BN0W2W23.USD","BK4585","LU0889565916.HKD","BK4588","BK4139","IE00BN0W2V16.EUR","ASRT","LU2210150020.SGD","JAZZ","LU2095319765.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","LU2210149790.SGD","LU0823416689.USD"],"gpt_icon":0},{"id":"2582374123","title":"Immix Biopharma Appoints Chief Commercial Officer to Drive Nxc-201 Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374123?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:45","pubTimestamp":1762955100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA3JJLHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2581837040","title":"Immix Biopharma Inc  expected to post a loss of 17 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581837040","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581837040?lang=en_us&edition=fundamental","pubTime":"2025-11-08 07:52","pubTimestamp":1762559524,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc  expected to post a loss of17cents a share - Earnings Preview Immix Biopharma Inc IMMX.OQ IMMX.O is expected to  report results on November 10 (estimated) for the period ending Dec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ34C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2580724727","title":"Immix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2580724727","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580724727?lang=en_us&edition=fundamental","pubTime":"2025-11-04 04:42","pubTimestamp":1762202555,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. has released a presentation highlighting the challenges faced by patients with relapsed or refractory AL amyloidosis in the United States. According to cited sources, approximately 34,000 US patients are affected by this life-threatening condition, which occurs when abnormal antibodies produce toxic light chains that accumulate in organs such as the heart, kidneys, and liver. The presentation outlines the limitations of current treatment options, especially after frontline therapies have failed. It notes that there are no approved drugs for patients with relapsed or refractory AL amyloidosis, and existing second-line therapies yield low complete response rates. The company emphasizes the need for improved therapeutic approaches to address these unmet medical needs. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL3Sq0SC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2580216922","title":"Immix Biopharma to Present Phase 1/2 NXC-201 CAR-T Trial Results for AL Amyloidosis at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580216922","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580216922?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:45","pubTimestamp":1762177518,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL5SqtQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU0314104364.USD","NDAQ","BK4588","BK4139","BK4112","LU2210150020.SGD","IMMX","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","LU2095319765.USD"],"gpt_icon":0},{"id":"2580216940","title":"Immix Biopharma’s Nxc-201 Nexicart-2 Clinical Trial Results Selected for Oral Presentation at Ash 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580216940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580216940?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:45","pubTimestamp":1762177500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA43GWNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2575187402","title":"Immix Biopharma Inc. to Present at Guggenheim Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575187402","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575187402?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:45","pubTimestamp":1760445908,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston from November 10-12, 2025. Management will participate in a fireside chat on November 11 at 12:30pm Eastern Time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on October 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL6L6cJd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IMMX","IE00B3QW5Z07.USD","BK4585","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4139"],"gpt_icon":0},{"id":"2574908721","title":"Immix Biopharma Inc publishes presentation highlighting leadership in relapsed and refractory AL Amyloidosis and promising NXC201 clinical data","url":"https://stock-news.laohu8.com/highlight/detail?id=2574908721","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574908721?lang=en_us&edition=fundamental","pubTime":"2025-10-09 05:49","pubTimestamp":1759960147,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc publishes presentation highlighting leadership in relapsed and refractory AL Amyloidosis and promising NXC201 clinical data. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on October 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL6SDjzL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":0.5248},{"period":"1month","weight":1.2848},{"period":"3month","weight":2.5143},{"period":"6month","weight":2.1404},{"period":"1year","weight":2.181},{"period":"ytd","weight":2.3545}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1544},{"period":"1year","weight":0.1345},{"period":"ytd","weight":0.1759}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.072585},{"month":2,"riseRate":0,"avgChangeRate":-0.16788},{"month":3,"riseRate":0,"avgChangeRate":-0.114009},{"month":4,"riseRate":0.5,"avgChangeRate":-0.026863},{"month":5,"riseRate":0.5,"avgChangeRate":0.112474},{"month":6,"riseRate":0.5,"avgChangeRate":0.09241},{"month":7,"riseRate":0.5,"avgChangeRate":0.015932},{"month":8,"riseRate":0.25,"avgChangeRate":-0.104667},{"month":9,"riseRate":0.25,"avgChangeRate":0.017421},{"month":10,"riseRate":0.75,"avgChangeRate":0.171445},{"month":11,"riseRate":1,"avgChangeRate":0.264693},{"month":12,"riseRate":1,"avgChangeRate":0.506474}],"exchange":"NASDAQ","name":"Immix Biopharma, Inc.","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immix Biopharma, Inc.,IMMX,Immix Biopharma, Inc.股票,Immix Biopharma, Inc.股票老虎,Immix Biopharma, Inc.股票老虎国际,Immix Biopharma, Inc.行情,Immix Biopharma, Inc.股票行情,Immix Biopharma, Inc.股价,Immix Biopharma, Inc.股市,Immix Biopharma, Inc.股票价格,Immix Biopharma, Inc.股票交易,Immix Biopharma, Inc.股票购买,Immix Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction